Comparative Pharmacology
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus ROBITET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus ROBITET.
DEMECLOCYCLINE HYDROCHLORIDE vs ROBITET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing aminoacyl-tRNA from attaching to the mRNA-ribosome complex.
Robitussin (Robitet) is a combination product containing the antitussive dextromethorphan and the expectorant guaifenesin. Dextromethorphan acts centrally on the cough center in the medulla oblongata by increasing the threshold for coughing, primarily through sigma-1 receptor agonism and NMDA receptor antagonism. Guaifenesin increases the hydration of respiratory tract secretions, reducing mucus viscosity and facilitating expectoration.
150 mg orally every 6 hours or 300 mg orally every 12 hours. Maximum daily dose: 1200 mg.
Tetracycline hydrochloride: 250-500 mg orally every 6 hours; maximum 4 g/day.
None Documented
None Documented
10-17 hours; prolonged in renal impairment (up to 40–50 hours)
Terminal elimination half-life: 3.5 hours (2.6–4.8 h) in adults; prolonged to 6–12 h in severe renal impairment
Renal: 40-50% unchanged; fecal/biliary: 10-15%
Renal: 30% unchanged; biliary/fecal: 50% as metabolites; remainder metabolized
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic